Intelligence · Patents
Patents expiring in 2045
Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.
- Patents
- 1,566
Quick answer
1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 12285397
Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
granted -
US 12285460
Pharmaceutical compositions
granted -
US 12286431
Crystalline forms of a KRas G12C inhibitor
granted -
US 12286630
Treatment methods for muscular dystrophy
granted -
US 12286480
Modulators of ROR1-ROR2 binding
granted -
US 12286483
Method of treating cancer using CD137 antibodies and PD-1 antagonists
granted -
US 12286405
Scalable synthesis of dual-target inhibitor of cannabinoid-1 receptor and inducible nitric oxide synthase
granted -
US 12286395
Method of synthesis of an ionizable cationic lipid
granted -
US 12286402
Compounds and their use for the treatment of alpha1-antitrypsin deficiency
granted -
US 12286400
Isofagomine salts, methods of use and formulations
granted -
US 12285627
Fabrication and irradiation of a radioactive isotope skin patch
granted -
US 12285485
Methods of treating pain
granted -
US 12285490
ASH1L degraders and methods of treatment therewith
granted -
US 12285472
Self-antigen displaying nanoparticles targeting auto-reactive immune factors and uses thereof
granted -
US 12285447
Methods and compositions for treating ulcerative colitis
granted -
US 12285435
Multivesicular liposome formulations of dexamethasone
granted -
US 12285419
Bupivacaine multivesicular liposome formulations and uses thereof
granted -
US 12285424
Methods for treating neutropenia
granted -
US 12285417
Methods for treating chronic obstructive pulmonary disease
granted -
US 12285392
Method for modulating metabolism
granted -
WO 2025090858
PROCÉDÉS D'IDENTIFICATION DE VARIANTS DE CAPSIDE DE VAA AYANT DES CARACTÉRISTIQUES SOUHAITÉES
granted -
WO 2025090898
ANTICORPS ANTI-RÉCEPTEUR DE LA TRANSFERRINE ET LEURS UTILISATIONS - RÉFÉRENCES CROISÉES AUX DEMANDES CONNEXES
granted -
US 12290651
Devices and methods for the treatment of body surface disorders
granted -
US 12291709
Compositions and methods for modulating apolipoprotein (a) expression
granted -
US 12291559
Compositions and methods for treating cancer
granted -
US 12290069
Pest control using natural pest control agent blends
granted -
US 12291571
Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody
granted -
US 12290573
Modified RNAi agents
granted -
US 12290597
Oral film compositions and dosage forms having precise active dissolution profiles
granted -
US 12291548
Compounds, compositions, and methods for the treatment of disease
granted -
US 12290520
Methods of use of emulsion formulations of aprepitant
granted -
US 12290551
Methods for imaging and treatment of somatostatin-receptor positive tumors
granted -
US 12290538
Methods and products for treatment of gastrointestinal disorders
granted -
US 12291508
Hydrazide containing nuclear transport modulators and uses thereof
granted -
US 12291533
Substituted fused pyrimidine compounds and uses thereof
granted -
US 12292441
Recombinant Acinetobacter baumannii strain AB5075
granted -
US 12292445
Methods of selecting subjects for treatment with metabolomic modulators
granted -
US 12291576
Anti-CD45 antibodies and conjugates thereof
granted -
US 12291556
Parathyroid hormone variants
granted -
US 12291565
Tau binding compounds
granted -
US 12291560
Dimerizing agent regulated immunoreceptor complexes
granted -
US 12291557
Chimeric TIM4 receptors and uses thereof
granted -
US 12291507
Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency
granted -
US 12291502
Topoisomerase II-alpha inhibitors and methods of treating cancer using the same
granted -
US 12291058
Dispersions for additive manufacturing comprising discrete carbon nanotubes
granted -
US 12291530
GLP-1R agonist and therapeutic method thereof
granted -
US 12290567
Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugates
granted -
US 12290588
Peptide having activity of improving skin condition and use thereof
granted
Frequently asked questions
How many pharma patents expire in 2045?
1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.